help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on January 21, 2005, doi:10.1164/rccm.200404-571OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200404-571OCv1
171/9/1040    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Azuma, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Azuma, A.
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 1040-1047, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200404-571OC

Original Article

Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi, Atsuhiko Sato, Shoji Kudoh for the members of the Research Group for Diffuse Lung Diseases in Japan; and Ganesh Raghu

Fourth Department of Internal Medicine, Nippon Medical School; Division of Respiratory Disease, Toranomon Hospital, Tokyo; Department of Respiratory Oncology and Molecular Medicine Division of Cancer Control Institute of Development, Aging, and Cancer, Tohoku University, Sendai; Department of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto; Third Department of Internal Medicine and Department of Biochemistry, Sapporo Medical University School of Medicine, Sapporo; Department of Respiratory Medicine, Tenri Hospital, Tenri; Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University; Kyoto Preventive Medical Center, Kyoto; Department of Radiology, Fukui Medical School, Fukui; Sleep Medical Center, Osaka Kaisei Hospital, Osaka, Japan; and University of Washington Medical Center, Seattle, Washington

Correspondence and requests for reprints should be addressed to Ganesh Raghu, M.D., Division of Pulmonary & Critical Care Medicine, Campus Box 356522, University of Washington, Seattle, WA 98195-6522. E-mail: graghu{at}u.washington.edu

Idiopathic pulmonary fibrosis (IPF) is a fatal disorder without an effective therapy to date. In a double-blind, randomized, placebo-controlled trial, 107 patients were prospectively evaluated for efficacy of a novel compound, pirfenidone. The difference in the change in the lowest oxygen saturation by pulse oximetry (SpO2) during a 6-minute exercise test, the primary endpoint, from baseline to 6 months was not significant between the two groups (p = 0.0722). In a prespecified subset of patients who maintained a SpO2 greater than 80% during a 6-minute exercise test at baseline, the lowest SpO2 improved during a 6-minute exercise test in the pirfenidone group at 6 and 9 months (p = 0.0069 and 0.0305, respectively). Positive treatment effect was demonstrated in secondary endpoints: (1) change in VC measurements at 9 months (p = 0.0366) and (2) episodes of acute exacerbation of IPF occurring exclusively in the placebo group during the 9 months (p = 0.0031). Significant adverse events were associated with pirfenidone; however, adherence to treatment regimen was similar between pirfenidone and placebo groups. In conclusion, treatment with pirfenidone improved VC and prevented acute exacerbation of IPF during the 9 months of follow-up. Future long-term studies are needed to clarify the overall safety and efficacy of pirfenidone in IPF.

Key Words: acute exacerbation • antifibrotic agent • idiopathic pulmonary fibrosis • pirfenidone • 6-minute steady-state exercise test




This article has been cited by other articles:


Home page
 ThoraxHome page
J J Swigris, X Zhou, F S Wamboldt, R du Bois, R Keith, A Fischer, G P Cosgrove, S K Frankel, D Curran-Everett, and K K Brown
Exercise peripheral oxygen saturation (Spo2) accurately reflects arterial oxygen saturation (Sao2) and predicts mortality in systemic sclerosis
Thorax, July 1, 2009; 64(7): 626 - 630.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
K. Sakamoto, H. Taniguchi, Y. Kondoh, K. Ono, Y. Hasegawa, and M. Kitaichi
Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease
Eur. Respir. Rev., June 1, 2009; 18(112): 129 - 132.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Tyndall, M. Matucci-Cerinic, and U. Muller-Ladner
Future targets in the management of systemic sclerosis
Rheumatology, June 1, 2009; 48(suppl_3): iii49 - iii53.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. M. Antoniou, G. Margaritopoulos, F. Economidou, and N. M. Siafakas
Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement
Eur. Respir. J., April 1, 2009; 33(4): 882 - 896.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
K. K. Brown and A. U. Wells
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Eur. Respir. Rev., December 1, 2008; 17(109): 116 - 122.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
T J Williams and J W Wilson
Authors' reply
Thorax, December 1, 2008; 63(12): 1121 - 1121.
[Full Text] [PDF]

Home page
 ThoraxHome page
T M Maher and A U Wells
Optimal treatment for idiopathic pulmonary fibrosis
Thorax, December 1, 2008; 63(12): 1120 - 1121.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. Jackson and C. D. Fell
Etanercept for Idiopathic Pulmonary Fibrosis: Lessons on Clinical Trial Design
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 889 - 891.
[Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
R. Kim and K. C. Meyer
Review: Therapies for interstitial lung disease: past, present and future
Therapeutic Advances in Respiratory Disease, October 1, 2008; 2(5): 319 - 338.
[Abstract] [PDF]

Home page
 ChestHome page
A. L. Olson, T. J. Huie, S. D. Groshong, G. P. Cosgrove, W. J. Janssen, M. I. Schwarz, K. K. Brown, and S. K. Frankel
Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis: A Case Series
Chest, October 1, 2008; 134(4): 844 - 850.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui
Interstitial lung disease guideline
Thorax, September 1, 2008; 63(Suppl_5): v1 - v58.
[Full Text] [PDF]

Home page
 ChestHome page
E. R. Fernandez-Perez, M. Yilmaz, H. Jenad, C. E. Daniels, J. H. Ryu, R. D. Hubmayr, and O. Gajic
Ventilator Settings and Outcome of Respiratory Failure in Chronic Interstitial Lung Disease
Chest, May 1, 2008; 133(5): 1113 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Ther Adv Respir DisHome page
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis
Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93.
[Abstract] [PDF]

Home page
 Eur Respir JHome page
A. Clement and E. Eber
Interstitial lung diseases in infants and children
Eur. Respir. J., March 1, 2008; 31(3): 658 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells, P. Latsi, and W. J. McCune
Daily Cyclophosphamide for Scleroderma: Are Patients with the Most to Gain Underrepresented in this Trial?
Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 952 - 953.
[Full Text] [PDF]

Home page
 ChestHome page
R. Hyzy, S. Huang, J. Myers, K. Flaherty, and F. Martinez
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Chest, November 1, 2007; 132(5): 1652 - 1658.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R. du Bois and T. E King Jr
Challenges in pulmonary fibrosis {middle dot} 5: The NSIP/UIP debate
Thorax, November 1, 2007; 62(11): 1008 - 1012.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. J. Scotton and R. C. Chambers
Molecular Targets in Pulmonary Fibrosis: The Myofibroblast in Focus
Chest, October 1, 2007; 132(4): 1311 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. R. Collard, B. B. Moore, K. R. Flaherty, K. K. Brown, R. J. Kaner, T. E. King Jr., J. A. Lasky, J. E. Loyd, I. Noth, M. A. Olman, et al.
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., October 1, 2007; 176(7): 636 - 643.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Shi, J. Wu, H. Chen, H. Chen, J. Wu, and F. Zeng
Single- and Multiple-Dose Pharmacokinetics of Pirfenidone, an Antifibrotic Agent, in Healthy Chinese Volunteers
J. Clin. Pharmacol., October 1, 2007; 47(10): 1268 - 1276.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
M. E. Cho, D. C. Smith, M. H. Branton, S. R. Penzak, and J. B. Kopp
Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 906 - 913.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
F. S. Shihab
Do We Have a Pill for Renal Fibrosis?
Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 876 - 878.
[Full Text] [PDF]

Home page
 ChestHome page
I. Noth and F. J. Martinez
Recent Advances in Idiopathic Pulmonary Fibrosis
Chest, August 1, 2007; 132(2): 637 - 650.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I-N. Park, D. S. Kim, T. S. Shim, C.-M. Lim, S. D. Lee, Y. Koh, W. S. Kim, W. D. Kim, S. J. Jang, and T. V. Colby
Acute Exacerbation of Interstitial Pneumonia Other Than Idiopathic Pulmonary Fibrosis
Chest, July 1, 2007; 132(1): 214 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. Richeldi and E. Abraham
Identifying Patients with Idiopathic Pulmonary Fibrosis: Quality or Quantity?
Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 976 - 977.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Gunther, B. Enke, P. Markart, P. Hammerl, H. Morr, J. Behr, G. Stahler, W. Seeger, F. Grimminger, I. Leconte, et al.
Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
Eur. Respir. J., April 1, 2007; 29(4): 713 - 719.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660.
[Full Text] [PDF]

Home page
 ThoraxHome page
R. M Rudd, R. J Prescott, J C Chalmers, I. D A Johnston, and for the Fibrosing Alveolitis Subcommittee of the R
British Thoracic Society Study on cryptogenic fibrosing alveolitis: response to treatment and survival
Thorax, January 1, 2007; 62(1): 62 - 66.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. E. Heffner
Update in pulmonary medicine.
Ann Intern Med, November 21, 2006; 145(10): 765 - 773.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Hill, A. Papafili, H. Booth, P. Lawson, M. Hubner, H. Beynon, C. Read, G. Lindahl, R. P. Marshall, R. J. McAnulty, et al.
Functional Prostaglandin-Endoperoxide Synthase 2 Polymorphism Predicts Poor Outcome in Sarcoidosis
Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 915 - 922.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
O.J. Dempsey, K.M. Kerr, L. Gomersall, H. Remmen, and G.P. Currie
Idiopathic pulmonary fibrosis: an update
QJM, October 1, 2006; 99(10): 643 - 654.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A B Millar
IL-10: another therapeutic target in idiopathic pulmonary fibrosis?
Thorax, October 1, 2006; 61(10): 835 - 836.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. R. Flaherty, A.-C. Andrei, S. Murray, C. Fraley, T. V. Colby, W. D. Travis, V. Lama, E. A. Kazerooni, B. H. Gross, G. B. Toews, et al.
Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test
Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 803 - 809.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. J. Lederer, S. M. Arcasoy, J. S. Wilt, F. D'Ovidio, J. R. Sonett, and S. M. Kawut
Six-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 659 - 664.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G. Raghu
Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches.
Eur. Respir. J., September 1, 2006; 28(3): 463 - 465.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Hirano, A. Kanehiro, K. Ono, W. Ito, A. Yoshida, C. Okada, H. Nakashima, Y. Tanimoto, M. Kataoka, E. W. Gelfand, et al.
Pirfenidone Modulates Airway Responsiveness, Inflammation, and Remodeling after Repeated Challenge
Am. J. Respir. Cell Mol. Biol., September 1, 2006; 35(3): 366 - 377.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. Lebtahi, S. Moreau, S. Marchand-Adam, M.-P. Debray, M. Brauner, P. Soler, J. Marchal, O. Raguin, A. Gruaz-Guyon, J.-C. Reubi, et al.
Increased Uptake of 111In-Octreotide in Idiopathic Pulmonary Fibrosis
J. Nucl. Med., August 1, 2006; 47(8): 1281 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. J. Martinez and M. P. Keane
Update in diffuse parenchymal lung diseases 2005.
Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1066 - 1071.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Inayama, Y. Nishioka, M. Azuma, S. Muto, Y. Aono, H. Makino, K. Tani, H. Uehara, K. Izumi, A. Itai, et al.
A Novel I{kappa}B Kinase-beta Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice
Am. J. Respir. Crit. Care Med., May 1, 2006; 173(9): 1016 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A. U. Wells
Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled.
Eur. Respir. J., April 1, 2006; 27(4): 664 - 666.
[Full Text] [PDF]

Home page
 NEJMHome page
J. H.K. Hull, T. P. Toma, A. Bhowmik, R. Rajakulasingam, M. Demedts, R. Buhl, U. Costabel, and the IFIGENIA Study Group
Acetylcysteine in Pulmonary Fibrosis
N. Engl. J. Med., March 9, 2006; 354(10): 1089 - 1091.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
F. J. Martinez
Idiopathic Interstitial Pneumonias: Usual Interstitial Pneumonia versus Nonspecific Interstitial Pneumonia.
Proceedings of the ATS, January 1, 2006; 3(1): 81 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. S. Kim, H. R. Collard, and T. E. King Jr.
Classification and natural history of the idiopathic interstitial pneumonias.
Proceedings of the ATS, January 1, 2006; 3(4): 285 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
N. Walter, H. R. Collard, and T. E. King Jr.
Current perspectives on the treatment of idiopathic pulmonary fibrosis.
Proceedings of the ATS, January 1, 2006; 3(4): 330 - 338.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Demedts, J. Behr, R. Buhl, U. Costabel, R. Dekhuijzen, H. M. Jansen, W. MacNee, M. Thomeer, B. Wallaert, F. Laurent, et al.
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis.
N. Engl. J. Med., November 24, 2005; 353(21): 2229 - 2242.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. W. Hunninghake
Antioxidant Therapy for Idiopathic Pulmonary Fibrosis.
N. Engl. J. Med., November 24, 2005; 353(21): 2285 - 2287.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
W. C. Johnson and G. Raghu
Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures
Eur. Respir. J., November 1, 2005; 26(5): 755 - 758.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
G. Tino
Clinical Year in Review III: Sleep-disordered Breathing, Interstitial Lung Disease, Lung Transplantation, and Pediatric Pulmonary Disease
Proceedings of the ATS, November 1, 2005; 2(4): 251 - 254.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. C. Mathai and A. J. Polito
The Questionable Efficacy of Pirfenidone in IPF
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1228 - 1228.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. Raghu
Poor Choice of Primary Outcome in a Clinical Trial of Pirfenidone in Patients with IPF
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1229 - 1230.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. Levitt and M. K. Gould
Poor Choice of Primary Outcome in a Clinical Trial of Pirfenidone in Patients with IPF
Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1228 - 1229.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
D. Bouros and K. M. Antoniou
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Eur. Respir. J., October 1, 2005; 26(4): 693 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. E. King Jr.
Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 268 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. M. du Bois
Is Idiopathic Pulmonary Fibrosis Now Treatable?
Am. J. Respir. Crit. Care Med., May 1, 2005; 171(9): 939 - 940.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society 		  Red Transition